Sotorasib for Lung Cancers with KRAS p.G12C Mutation von Skoulidis, Ferdinandos, Li, Bob T, Dy, Grace K, Price, Timothy J, Falchook, Gerald S, Wolf, Jürgen, Italiano, Antoine, Schuler, Martin, Borghaei, Hossein, Barlesi, Fabrice, Kato, Terufumi, Curioni-Fontecedro, Alessandra, Sacher, Adrian, Spira, Alexander, Ramalingam, Suresh S, Takahashi, Toshiaki, Besse, Benjamin, Anderson, Abraham, Ang, Agnes, Tran, Qui, Mather, Omar, Henary, Haby, Ngarmchamnanrith, Gataree, Friberg, Gregory, Velcheti, Vamsidhar, Govindan, Ramaswamy

Volltext

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma von Gluck, W. Larry, Gounder, Mrinal M., Frank, Richard, Eskens, Ferry, Blay, Jean Yves, Cassier, Philippe A., Soria, Jean-Charles, Chawla, Sant, de Weger, Vincent, Wagner, Andrew J., Siegel, David, De Vos, Filip, Rasmussen, Erik, Henary, Haby A.

Volltext

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII von Rosenthal, Mark, Curry, Richard, Reardon, David A., Rasmussen, Erik, Upreti, Vijay V., Damore, Michael A., Henary, Haby A., Hill, John S., Cloughesy, Timothy

Volltext

Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria von Kulasekararaj, Austin, Lanza, Francesco, Arvanitakis, Alexandros, Langemeijer, Saskia, Chonat, Satheesh, Tombak, Anil, Hanes, Vladimir, Cao, Jia, Miller, Mieke Jill, Colbert, Alexander, Shander, Benjamin, Mytych, Daniel T., Chow, Vincent, Henary, Haby

Volltext

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia von Erba, Harry P., Becker, Pamela S., Shami, Paul J., Grunwald, Michael R., Flesher, Donna L., Zhu, Min, Rasmussen, Erik, Henary, Haby A., Anderson, Abraham A., Wang, Eunice S.

Volltext

Sotorasib for previously treated colorectal cancers with KRAS G12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial von Fakih, Marwan G, Kopetz, Scott, Kuboki, Yasutoshi, Kim, Tae Won, Munster, Pamela N, Krauss, John C, Falchook, Gerald S, Han, Sae-Won, Heinemann, Volker, Muro, Kei, Strickler, John H, Hong, David S, Denlinger, Crystal S, Girotto, Gustavo, Lee, Myung-Ah, Henary, Haby, Tran, Qui, Park, Joseph K, Ngarmchamnanrith, Gataree, Prenen, Hans, Price, Timothy J

Volltext

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study von Moschos, Stergios J., Sandhu, Shahneen, Lewis, Karl D., Sullivan, Ryan J., Puzanov, Igor, Johnson, Douglas B., Henary, Haby A., Wong, Hansen, Upreti, Vijay V., Long, Georgina V., Flaherty, Keith T.

Volltext

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory r... von Massard, Christophe, Soria, Jean-Charles, Krauss, Jürgen, Gordon, Michael, Lockhart, Albert Craig, Rasmussen, Erik, Upreti, Vijay V., Patel, Sonal, Ngarmchamnanrith, Gataree, Henary, Haby

Volltext

PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEM... von Kulasekararaj, Austin, Lanza, Francesco, Arvanitakis, Alexandros, Langemeijer, Saskia, Chonat, Satheesh, Cao, Jia, Chow, Vincent, Henary, Haby

Volltext

KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors von Hong, David S., Fakih, Marwan G., Strickler, John H., Desai, Jayesh, Durm, Gregory A., Shapiro, Geoffrey I., Falchook, Gerald S., Price, Timothy J., Sacher, Adrian, Denlinger, Crystal S., Bang, Yung-Jue, Dy, Grace K., Krauss, John C., Kuboki, Yasutoshi, Kuo, James C., Coveler, Andrew L., Park, Keunchil, Kim, Tae Won, Barlesi, Fabrice, Munster, Pamela N., Ramalingam, Suresh S., Burns, Timothy F., Meric-Bernstam, Funda, Henary, Haby, Ngang, Jude, Ngarmchamnanrith, Gataree, Kim, June, Houk, Brett E., Canon, Jude, Lipford, J. Russell, Friberg, Gregory, Lito, Piro, Govindan, Ramaswamy, Li, Bob T.

Volltext

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity von Canon, Jude, Rex, Karen, Saiki, Anne Y., Mohr, Christopher, Cooke, Keegan, Bagal, Dhanashri, Gaida, Kevin, Holt, Tyler, Knutson, Charles G., Koppada, Neelima, Lanman, Brian A., Werner, Jonathan, Rapaport, Aaron S., San Miguel, Tisha, Ortiz, Roberto, Osgood, Tao, Sun, Ji-Rong, Zhu, Xiaochun, McCarter, John D., Volak, Laurie P., Houk, Brett E., Fakih, Marwan G., O’Neil, Bert H., Price, Timothy J., Falchook, Gerald S., Desai, Jayesh, Kuo, James, Govindan, Ramaswamy, Hong, David S., Ouyang, Wenjun, Henary, Haby, Arvedson, Tara, Cee, Victor J., Lipford, J. Russell

Volltext

Efficacy of Parallel and Crossover Analysis As Well As Pharmacokinetic Similarity Were Confirmed between ABP 959 and Eculizumab Reference Product in Patients with PNH von Kulasekararaj, Austin, Lanza, Francesco, Arvanitakis, Alexandros, Langemeijer, Saskia MC, Chonat, Satheesh, Cao, Jia, Chow, Vincent, Henary, Haby

Volltext

A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate von Amato, Robert J., D.O, Teh, Bin S., M.D, Henary, Haby, M.D, Khan, Muhammad, M.D, Saxena, Somyata, B.S

Volltext

Efficacy and Safety of Biosimilar Candidate ABP 959 As Compared with Eculizumab Reference Product in Paroxysmal Nocturnal Hemoglobinuria von Kulasekararaj, Austin, Lanza, Francesco, Arvanitakis, Alexandros, Langemeijer, Saskia M.C., Chonat, Satheesh, Chow, Vincent, Pan, Jean, Saportas, Yaneth, Hanes, Vladimir, Henary, Haby

Volltext

Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate von Amato, Robert J., D.O, Hernandez-McClain, Joan, M.P.H, Henary, Haby, M.D

Volltext

Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS G12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumo... von Fakih, Marwan, Durm, Greg Andrew, Govindan, Ramaswamy, Falchook, Gerald Steven, Soman, Neelesh, Henary, Haby Adel, Hong, David S.

Volltext

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial von Fakih, Marwan G, Kopetz, Scott, Kuboki, Yasutoshi, Kim, Tae Won, Munster, Pamela N, Krauss, John C, Falchook, Gerald S, Han, Sae-Won, Heinemann, Volker, Muro, Kei, Strickler, John H, Hong, David S, Denlinger, Crystal S, Girotto, Gustavo, Lee, Myung-Ah, Henary, Haby, Tran, Qui, Park, Joseph K, Ngarmchamnanrith, Gataree, Prenen, Hans, Price, Timothy J

Volltext

CodeBreak 100: Phase I study of AMG 510, a novel KRAS G12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal canc... von Hong, David S., Kuo, James, Sacher, Adrian G., Barlesi, Fabrice, Besse, Benjamin, Kuboki, Yasutoshi, Dy, Grace K., Dembla, Vikas, Krauss, John C., Burns, Timothy F., Kim, June, Henary, Haby, Ngarmchamnanrith, Gataree, Li, Bob T.

Volltext

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS G12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in... von Hong, David S., Strickler, John H., Fakih, Marwan, Falchook, Gerald Steven, Li, Bob T., Durm, Greg Andrew, Burns, Timothy F., Ramalingam, Suresh S., Goldberg, Sarah B., Frank, Richard C., Marrone, Kristen, Shu, Catherine A., Gandara, David R., Soman, Neelesh, Henary, Haby Adel, Govindan, Ramaswamy

Volltext

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRAS G12C inhibitor, in advanced solid tumors von Fakih, Marwan, O'Neil, Bert, Price, Timothy Jay, Falchook, Gerald Steven, Desai, Jayesh, Kuo, James, Govindan, Ramaswamy, Rasmussen, Erik, Morrow, Phuong Khanh H., Ngang, Jude, Henary, Haby A., Hong, David S.

Volltext